Renal involvement in systemic sclerosis;Atteintes rènales sclérodermiques

Revue du Praticien

Volumn 52, Issue 17, 2002, Pages 1910-1914

  Boffa, Jean Jacques ^a   Rossert, Jérôme ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINOXIDIL;

HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; MALIGNANT HYPERTENSION; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; PROGNOSIS; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR LESION; BIOPSY; HOSPITALIZATION; RENOVASCULAR HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; BIOPSY; HUMANS; HYPERTENSION, RENAL; KIDNEY DISEASES; PROGNOSIS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 0036827276     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Silman AJ. Epidemiology of scleroderma. Ann Rheum Dis 1991; 50: 846-53.
2. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
3. Moore HC, Sheehan HL. The kidney of scleroderma. Lancet 1952; 1: 68-70.
4. Zeng X, Chen J, Dong Y. Clinicopathological study of renal involvement in patients with systemic sclerosis. Chin Med J 1998 111: 224-7.
5. Oliver JA, Cannon PJ. The kidney in scleroderma. Nephron 1977; 18: 141.
6. Bonnet F, Longy-Boursier M, Aparicio M et al. La crise rénale sclérodermique.Ann Med Interne 1998; 149: 243-50.
7. Traub YM, Shapiro AP, Rodnan GP et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine 1983; 62: 335-52.
8. Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76: 779-86.
9. Haviv YS, Safadi R. Normotensive scleroderma renal crisis: Case report and review of the literature. Renal Fail 1998; 20: 733-6.
10. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999; 117: 395-402.
11. Simon NM, Graham MB, Kyser FA, Gashti EN. Resolution of renal failure with malignant hypertension in scleroderma. Case report and review of the literature. Am J Med 1979; 67: 533-9.
12. Lopez-Ovejero JA, Saal SD, D'Angelo WA, Cheigh JS, Stenzel KH, Laragh JH. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979; 300: 1417-9.
13. Thurm RH, Alexander JC. Captopril in the treatment of scleroderma renal crisis. Arch Intern Med 1984; 144: 733-5.
14. Zawada ET Jr, Clements PJ, Furst DA, Bloomer HA, Paulus HE, Maxwell MH. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 1981; 27: 74-8.
15. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352-7.
16. Hasegawa S, lesato K, Tsukahara T et al. Successful use of angiotensin II receptor antagonist (losartan) in a patient with scleroderma renal crisis Nippon Jinzo Gakkai Shi 2000; 42: 60-5.
17. Chang YJ, Spiera H. Renal transplantation in scleroderma. Medicine 1999; 78: 382-5.
18. Bleyer AJ, Donaldson LA, McIntosh M, Adams PL. Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis 2001; 37: 1152-61.
19. Ruiz JC, Val F, de Francisco AL et al. Progressive systemic sclerosis and renal transplantation: A contraindication to the use of cyclosporine A? Transplant Proc 1991; 23: 221-2.
20. Kikuchi K, Sato S, Kadono T, Ihn H, Takehara K. Serum concentration of procollagen type I carboxyterminal propeptide in localized scleroderma. Arch Dermatol 1994; 130: 1269-72.
21. Yazawa N, Kikuchi K, Ihn H et al. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol 2000; 42: 70-5.
22. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-75.
23. Duncan MR, Frazier KS, Abramson S et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Down-regulation by cAMP. FASEB J 1999; 13: 1774-86.
24. Clements PJ, Lachenbruch PA, Furst DE, Maxwell M, Danovitch G, Paulus HE.Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year follow up. Arthritis Rheum 1994; 37: 67-74.
25. D'Angelo WA, Fries JF, Masi AT, Schulman LE. Pathologic observations in systemic sclerosis. Am J Med 1969; 46: 428-40.
26. Hall CL, Jawad S, Harrison PR et al. Natural course of penicillamine nephropathy: A long term study of 33 patients. BMJ 1988; 296: 1083-6.
27. Marchand-Courville S, Dhib M, Fillastre JP, Godin M. Glomérulmonéphrites extracapillaires secondaires à la D-penicillamine. À propos d'une observation et revue de la littérature. Néphrologie 1998; 19: 25-32.
28. Karpinski J, Jothy S, Radoux V, Levy M, Baran D. D-penicillamine-induced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature. Am J Nephrol 1997; 17: 528-32.
29. Kyndt X, Ducq P, Bridoux F et al. Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D. Presse Med 1999; 28: 67-70.
30. Katrib A, Sturgess A, Bertouch JV. Systemic sclerosis and antineutrophil cytoplasmic autoantibody-associated renal failure. Rheumatol Int 1999; 19: 61-3.
31. Yamashita K, Yorioka N, Kyuden Y et al. A case of CREST syndrome and myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin Nephrol 2000; 53: 296-300.
32. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.